CNSY catalyst calendar

CERENOME, INC.

Upcoming catalysts
3
Cash runway
4.1 months
Cash & investments
$9M

CERENOME, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.

The next scheduled catalyst is Next quarterly earnings (projected) on October 30, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 4.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
October 30, 2026 est. Next quarterly earnings (projected) Earnings —
March 1, 2028 Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment Trial Milestone Phase 1
March 15, 2028 Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma Trial Milestone Phase 1

Track CNSY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open CNSY in the tracker

Recent history

DateEventTypePhase
October 2, 2026 8-K filed: Other event Filing —
October 2, 2026 Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Trial Milestone Phase 1/Phase 2
September 10, 2026 8-K filed: Material agreement, Other event Corporate —
August 14, 2026 Quarterly results filed (8-K) Earnings —
June 5, 2026 8-K filed: Material agreement Corporate —
May 15, 2026 Quarterly results filed (8-K) Earnings —
April 21, 2026 8-K filed: Other event Filing —
April 9, 2026 8-K filed: Leadership change Corporate —
April 8, 2026 8-K filed: Other event Filing —
April 2, 2026 8-K filed: Other event Filing —
March 26, 2026 8-K filed: Leadership change Corporate —
March 12, 2026 Quarterly results filed (8-K) Earnings —
March 12, 2026 8-K filed: Other event Filing —
February 13, 2026 8-K filed: Leadership change Corporate —
January 22, 2026 8-K filed: Other event Filing —
January 16, 2026 8-K filed: Material agreement, Other event Corporate —
December 21, 2025 Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Trial Milestone Phase 1
December 15, 2025 Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) Trial Milestone Phase 1/Phase 2
November 17, 2025 8-K filed: Reg FD disclosure, Other event Filing —
October 30, 2025 Quarterly results filed (8-K) Earnings —
October 21, 2025 8-K filed: Material agreement Corporate —
August 26, 2025 8-K filed: Other event Filing —
August 14, 2025 Quarterly results filed (8-K) Earnings —
August 14, 2025 8-K filed: Other event Filing —
August 13, 2025 8-K filed: Other event Filing —
June 20, 2025 8-K filed: Material agreement Corporate —
June 17, 2025 8-K filed: Material agreement Corporate —
June 6, 2025 8-K filed: Listing / standard notice Corporate —
May 30, 2025 Quarterly results filed (8-K) Earnings —
May 23, 2025 8-K filed: Listing / standard notice, Reg FD disclosure Corporate —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.